Hims & Hers Health, Inc. (HIMS) is at a pivotal moment. The telehealth platform, currently trading at $31.77, has delighted investors with significantly raised revenue guidance for fiscal year 2026, now projected to reach $3.1-3.3 billion. This upward revision, seen twice already this year, suggests robust demand across its platform. However, a deeper dive into recent financial reports reveals a troubling counter-trend: a precipitous decline in the company's gross margin. In Q2 2026, gross margin dropped to 64% from 76% in the same period last year, a stark 12 percentage point reduction. This compression marks a significant shift from Hims’s historical profile as a high-margin digital health provider.
The core of this tension lies in the company's aggressive expansion into GLP-1 weight-loss offerings, alongside growth in labs and international markets. While these initiatives are clearly fueling the top-line expansion, management has been explicit that these newer offerings carry a lower gross margin profile than its traditional telehealth specialties. The strategic pivot away from higher-margin compounded GLP-1s towards lower-margin branded products, driven by regulatory and legal pressures, has accelerated this margin erosion. For investors, the challenge is to reconcile a booming revenue outlook with a rapidly diminishing per-unit profitability, a dynamic that suggests the market may be rewarding volume without fully accounting for the underlying shift in HIMS's business economics.
The financial statements of Hims & Hers paint a clear picture of top-line expansion coupled with declining profitability on a percentage basis. From fiscal year 2023 to Q2 2026, gross margin has steadily eroded. In 2023, the company boasted an impressive 82% gross margin on revenue of $872.0 million. By 2025, with revenue more than doubling to $2,347.6 million, gross margin had fallen to 74%. The trend accelerated into 2026, with Q1 2026 reporting a GAAP gross margin of 65% and Q2 2026 falling further to 64%. This represents an 18 percentage point, or 1800 basis point, decline from its 2023 peak.
The cost of revenue has grown significantly faster than revenue. From 2024 to 2025, revenue increased by 59.0%, while the cost of revenue surged by 102.5%, nearly doubling year-over-year. This disproportionate growth in costs directly contributed to the gross margin compression. Had Hims maintained its 79% gross margin from 2024 on its 2025 revenue of $2,347.6 million, gross profit would have been approximately $1,854.6 million, a difference of $121.2 million compared to the $1,733.4 million actually reported. This shortfall clearly illustrates the magnitude of the GLP-1 driven margin drag. The table below highlights these key trends:
| Period | Revenue ($M) | Cost of Rev. ($M) | Gross Profit ($M) | Gross Margin (%) | Net Income (Loss) ($M) |
|---|---|---|---|---|---|
| FY 2023 | 872.0 | 157.1 | 714.9 | 82% | (23.5) |
| FY 2024 | 1,476.5 | 303.4 | 1,173.1 | 79% | 126.0 |
| FY 2025 | 2,347.6 | 614.3 | 1,733.4 | 74% | 128.4 |
| Q1 2025 | 586.0 | 155.3 | 430.7 | 73% | 49.5 |
| Q2 2025 | 544.8 | 128.6 | 416.2 | 76% | 42.5 |
| Q1 2026 | 608.1 | 211.3 | 396.8 | 65% | (92.1) |
| Q2 2026 | 753.2 | 272.4 | 480.8 | 64% | (86.3) |
The story of Hims & Hers's margin compression is inextricably linked to its foray into GLP-1 weight-loss treatments. Initially, Hims launched compounded semaglutide offerings in May 2024, rapidly scaling its GLP-1 revenue to approximately $230 million in Q1 2025 alone, representing roughly 39% of total revenue that quarter. This early compounded model, relying on in-house or partner pharmacies, likely offered a more favorable gross margin than standard branded drug distribution due to lower API costs and direct control over formulation.
However, this "compounding gold" proved short-lived. Regulatory scrutiny intensified in late 2025 and early 2026. The FDA announced its intent to restrict GLP-1 APIs used in non-FDA-approved compounded drugs, specifically naming Hims & Hers, and the HHS referred the company to the Department of Justice for potential violations. Simultaneously, Novo Nordisk filed a lawsuit against Hims over its compounded products. This culminated in a strategic pivot announced in March 2026, where Hims ceased advertising compounded GLP-1s and partnered with Novo Nordisk to offer FDA-approved branded GLP-1s like Ozempic and Wegovy.
This shift brought significant "financial noise," as management noted on the Q1 2026 earnings call. The company incurred approximately $33 million in restructuring costs, with $28.5 million of non-cash charges recorded in cost of revenue, primarily from write-downs related to its now-obsolete compounded GLP-1 supply chain. This one-time hit alone reduced Q1 2026 gross margin by roughly five percentage points, from an adjusted 70% to a GAAP 65%. Beyond these initial charges, the fundamental unit economics have changed. While management claims the unit economics between branded and compounded products are "roughly comparable" on a dollar basis, the company-wide gross margin data, declining to 64% in Q2 2026 without significant one-time charges, suggests otherwise. Distributing branded drugs inherently means thinner margins, as Hims becomes more of a channel for manufacturer-set pricing rather than a vertically integrated compounder.
While Hims & Hers boasts impressive subscriber growth—reaching nearly 2.9 million by Q2 2026, up from 2.5 million a year prior—and an increase in monthly online revenue per average subscriber (MORPAS) to $92 in Q2 2026, these metrics belie a critical underlying trend: the dilution of profitability per unit of revenue. Even as ARPU improves, driven by higher-ticket GLP-1 prescriptions, the gross margin continues to fall. This implies that the incremental revenue generated by these newer, high-volume offerings comes at a significantly lower gross margin percentage than the legacy telehealth specialties.
The company's CFO, Yemi Okupe, explicitly stated on the Q1 2026 earnings call that "we expect gross margins to compress as we prioritize scaling areas such as weight loss, labs, and international markets, which have a lower gross margin profile than our longer-tenured specialties." This commentary underscores that the growth narrative is deliberately being pursued through lower-margin avenues. The sheer volume of GLP-1 shipments, exceeding 125,000 within six weeks of introducing Novo Nordisk products, demonstrates the rapid scaling of these segments.
However, the rapid growth in international revenue, up more than 17-fold year-over-year in Q2 2026, also contributes to this margin headwind. Acquisitions in the international space, while expanding the company's footprint, often carry integration costs and different margin profiles. The combined effect is a scenario where more subscribers are generating more revenue, but each dollar of that revenue yields less gross profit for the company. The shift means Hims is increasingly trading its historical high-margin, software-like telehealth economics for a more pharmacy-like model with inherently thinner per-unit profitability, a trade-off that is not yet fully reflected in its valuation.
Hims & Hers faces several concrete risks that could further challenge its margin and profitability outlook. The most prominent is the structural gross margin compression already evident. A decline from 82% in 2023 to 64% in Q2 2026 represents a permanent shift in the company's profitability structure. If gross margin stabilizes near 64-65%, a revenue base of $3.0 billion would yield approximately $1.92-1.95 billion in gross profit, significantly less than the $2.22 billion that would have been generated at 2025's 74% margin. This roughly $270-300 million annual shortfall impacts earnings power.
Secondly, the regulatory and legal overhang from compounded GLP-1s remains a significant concern. While the Novo Nordisk settlement provides some clarity, the HHS referral to the Department of Justice for potential FDCA violations still carries the risk of civil penalties. The Q1 2026 restructuring costs of $33 million, largely tied to compounded GLP-1 write-downs, illustrate the financial impact of rapid regulatory shifts. Future enforcement actions, even if not directly targeting Hims, could affect the broader GLP-1 market and indirectly impact branded GLP-1 availability or pricing.
The company's guidance itself implies lower incremental margins. Despite repeatedly raising revenue guidance for 2026, management has simultaneously tightened or lowered its Adjusted EBITDA outlook. The 2026 Adjusted EBITDA guidance, now $275-325 million on $3.1-3.3 billion of revenue, implies a margin of roughly 9-10% at the midpoint, notably below the implied 13-14% Adjusted EBITDA margin in 2025. This pattern of higher revenue and lower proportional profit is a classic indicator of growth being bought at the expense of unit economics.
Finally, Hims's valuation appears rich relative to its current profitability and margin trajectory. With a trailing twelve-month (TTM) net margin of -5.5% and a TTM P/S of 2.75x, the stock is valued above many unprofitable digital health peers. Its P/FCF of 78.85x and negative EV/EBITDA of -83.33x underscore the thin or negative cash flow generation. This suggests that the market is pricing in a strong growth narrative and a future margin recovery that is not explicitly supported by current guidance or trends.
Wall Street analysts appear cautious on Hims & Hers, despite the company's impressive revenue growth. The consensus rating for HIMS is a "Hold," with 13 out of 20 analysts maintaining a Hold rating, and only 7 recommending a Buy. This reflects a significant degree of skepticism regarding the company's ability to translate top-line growth into sustainable profitability amidst the GLP-1 pivot.
The analyst price targets further highlight this uncertainty:
| Firm (Selected) | Rating | Price Target |
|---|---|---|
| Truist Securities | Hold | $28.00 |
| Citigroup | Neutral | $25.00 |
| JPMorgan | Buy | $35.00 |
| Morgan Stanley | Hold | $40.00 |
| TD Cowen | Hold | $30.00 |
| Leerink Partners | Hold | $25.00 |
| Consensus | Hold | $26.91 |
| Median | — | $25.00 |
| High | — | $40.00 |
| Low | — | $12.50 |
At its current price of $31.77, HIMS trades approximately 18% above the consensus target of $26.91 and 27% above the median target of $25.00. This suggests that the market is more optimistic than the average analyst, perhaps pricing in a more successful margin recovery or faster scale efficiencies than the Street anticipates. The wide spread between the low target of $12.50 and the high target of $40.00 underscores the significant disagreement and uncertainty surrounding HIMS's long-term value proposition, particularly as its business model shifts and its margin profile changes. The current premium to consensus implies limited upside if the Street's concerns about margin sustainability prove correct.
The strongest objection to the thesis of structural margin erosion for Hims & Hers lies in management's long-term aspirations. The company has reiterated a target of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA (a 20% Adjusted EBITDA margin) by 2030. This implies a significant rebound in profitability from the current 9-10% Adjusted EBITDA margin guided for 2026. Management contends that scale efficiencies, AI-driven operational improvements, and cross-selling across its platform will eventually offset the near-term margin compression from GLP-1s, labs, and international expansion.
However, the current evidence does not yet support a return to historical gross margin levels. Even after adjusting for the $28.5 million in one-time GLP-1 restructuring charges, Q1 2026 gross margin was roughly 70%, still a notable 12 percentage points below Q1 2024's 82%. Crucially, management has explicitly guided investors to expect "a couple of points" more gross margin compression in upcoming quarters, not a rebound. The shift from a compounded GLP-1 model, which allowed for higher margins through in-house production, to a branded distribution model, where Hims's take rate is likely constrained by manufacturer pricing, represents a permanent change in unit economics. While scale may improve operating leverage, it cannot fundamentally alter the lower gross margin profile of reselling branded pharmaceuticals.
The market's current valuation, trading above analyst consensus targets despite declining gross margins and negative net profitability, suggests an optimism that Hims will successfully navigate this transition and achieve its ambitious 2030 targets. Yet, the path to recovering gross margins to the mid-70s or higher, while GLP-1s continue to represent a substantial portion of revenue, remains unclear. What would definitively falsify the "low-margin GLP-1" thesis would be for Hims & Hers to report sustained gross margins of 70% or higher for the next two to three quarters, while simultaneously demonstrating that GLP-1 revenue continues to contribute materially to its top line. Absent this, the market continues to price in a recovery that the underlying financials have yet to demonstrate.
Hims & Hers is caught between aggressive revenue growth and a deteriorating margin structure. The company's strategic pivot into high-volume, lower-margin GLP-1s has fundamentally altered its financial profile, making "revenue up, profit per unit down" the prevailing dynamic. While top-line expansion continues, the persistent decline in gross margins, compounded by regulatory pressures and the shift to branded products, erodes the underlying profitability that historically justified its premium valuation. The current stock price of $31.77 trades above Wall Street's consensus, suggesting that the market has yet to fully price in the structural nature of this margin erosion.
Therefore, we take a Cautious stance on HIMS. An appropriate entry zone for new positions would be closer to the median analyst target, around $25.00, which better reflects the current margin challenges and the inherent risks. Our 12-month target is $30.00, implying modest upside if the company can stabilize its gross margins in the high-60s and continue its rapid subscriber growth, without further regulatory setbacks. However, this thesis would be invalidated if HIMS consistently reports quarterly gross margins below 62% or if 2026 Adjusted EBITDA guidance is cut below $250 million, signaling a more severe and entrenched profitability issue. Hims's future success now hinges less on revenue growth, and more on its ability to prove that its high-volume GLP-1 strategy can eventually yield meaningful, sustainable gross profit dollars.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
